Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV

By sjmartinez • October 22, 2024

Zanni MV, Umbleja T, Fichtenbaum CJ, Fitch KV, McCallum S, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Schnittman SR, Erlandson KM, Diggs MR, Foldyna B, Martinez E, Somboonwit C, Wang GP, Mushatt D, Connick E, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK. Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV. Open Forum Infect Dis. 2024 Oct 10;11(10):ofae574. doi: 10.1093/ofid/ofae574. PMID: 39435321; PMCID: PMC11493083.

Tags: covid-19, HIV, Infectious Diseases, Publications, PWH, REPRIEVE, statin

Related Posts

Healthcare provider and health system leader perspectives on barriers to hypertension care in Malawi: insights from integrated and non-integrated HIV care settings

Hagstrom C, Kalande P, Aryal A, Phiri K, van Oosterhout JJ, Talama G, Lungu E, Phiri S, Moucheraud C, Hoffman R. Healthcare provider and health[...]

Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2–LTR Circles Over 12 Weeks

Reed JC, Hall L, McKhann A, Kwak G, Goecker EA, Coombs RW, Chen H, Roa J, Vecchio A, Daar ES, Hunt PW, Marra CM, Campbell[...]

Author Correction: Barcoded HIV-1 reveals viral persistence driven by clonal proliferation and distinct epigenetic patterns

Zhang TH, Shi Y, Komarova NL, Wodarz D, Kostelny M, Gonzales A, Abbaali I, Chen H, Bresson-Tan G, Dimapasoc M, Harvey W, Oh C, Carmona[...]